A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies

Trial Details

NCT ID

NCT06820268

Phase

PHASE1

Sponsor

NovaOnco Therapeutics Co., Ltd.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• XS-04 tablet

Locations (sample)

• Beijing, China|39.9075,116.39723
• Guangdong, China|42.76832,129.33635
• Hebei, China|25.93504,116.17968
• Hubei, China|29.08114,120.41732

Key Eligibility Criteria

• Patients must meet all of the following conditions to be enrolled:
• Voluntarily participate in the clinical trial and sign the informed consent form (ICF).
• Age ≥18 years, ≤75 years, regardless of gender.
• Dose escalation phase: Patients with mature B-cell malignant tumors confirmed by histopathology according to the 2017 World Health Organization (WH…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.